Association of aldosterone synthase (CYP11B2 C-344T) gene polymorphism & susceptibility to essential hypertension in a south Indian Tamil population.
Material & Methods
Study population: The study was conducted from June 2005 to April 2008 in 406 unrelated essential hypertensive patients (200 males and 206 females) aged 30-60 yr who were residents of Tamil Nadu and Pondicherry for at least three generations. The subjects were selected randomly and the sample size was calculated using PS-Power and sample size calculation version 3.0 software. They were recruited from the outpatient clinics of hypertension and internal medicine of Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER) hospital, Puducherry in south India. Patients, who were receiving antihypertensive medications for more than 3 months or newly diagnosed hypertensive patients with systolic blood pressure (SBP) more than 140 mmHg and/or diastolic blood pressure (DBP) more than 90 mmHg on two or more consecutive visits were considered as hypertensives (22). Patients with history of diabetes mellitus, hyperlipidaemia, liver or renal disease, congestive cardiac failure and recent episode of myocardial infarction were excluded. Patients with pregnancy and lactation and receiving medications for other indications that could affect blood pressure were also excluded. The control group consisted of 424 (183 males and 241 females, aged between 25-60 yr) unrelated healthy volunteers. These subjects had no personal or family history of hypertension and other cardiovascular diseases in first-degree relatives and had SBP <130 mmHg and DBP <85 mmHg. Healthy volunteers from the health camp and patients who visited the outpatient clinics with minor illness without hypertension, diabetes mellitus, hyperlipidaemia and family history of hypertension in previous records were recruited as controls. none of the subjects in the control group was receiving antihypertensive therapy, treatment for heart disease or hormone-replacement therapy during the time of the study. Plasma lipid profile and blood glucose level were measured after overnight fasting in both hypertensives and normotensives to rule out diabetes and hyperlipidaemia. All the participants were interviewed using standardized questionnaire with regard to their lifestyle, smoking, alcohol consumption and drug intake. The questionnaire was prepared according to the British Hypertension Society guidelines by the clinicians in the department of medicine and hypertension clinic, JIPMER and Institute ethics committee approval was obtained. In all subjects, height was measured to the nearest centimeter and weight to the nearest 0.1 kg which were used for calculation of BMI (kg/[m.sup.2]). Blood pressure was measured two minutes apart three times in the right arm using standard sphygmomanometer after the subjects rested for 10 min and the average reading was recorded. The study was approved by the institutional ethics committee and written informed consent was obtained from all the participants.
Genotyping: Five milliliters of venous blood was collected from the participants using ethylene diamine tetra acetic acid (EDTA) as an anticoagulant and the genomic DNA was extracted using phenol-chloroform method. The CYP11B2 C-344T polymorphism was detected using PCR-RFLP method (5). PCR reaction was performed in mastercycler gradient (Eppendorf, AG, Hamburg, Germany) using 25 [micro]l reaction mixture containing 100 ng of DNA, 200 [micro]M of dNTPs, 0.2 [micro]M of each primers (Alpha DNA, Montreal, Canada) (Sense-5'-CAGGAGGAGACCCCATGTGAC-3'; antisense-5'-CCTCCA CCCTGTTCAGCCC-3'), 1.5 mM of Mg[Cl.sub.2] and 0.5 U of Taq DNA polymerase. This was subjected to 35 cycles with initial denaturation at 94[degrees]C for 5 min, cyclic denaturation at 94[degrees]C for 60 sec, followed by annealing at 67[degrees]C for 60 sec, extension at 72[degrees]C for 60 sec and a final extension at 72[degrees]C for 5 min. The amplification was checked in horizontal gel electrophoresis unit (Apelex, Massy cedex, France) using 1 per cent agarose gel followed by restriction digestion of the 538 bp PCR product with HaeIII endonuclease (New England Biolabs inc., IA, USA) for 2 h at 37[degrees]C. The digested product was analyzed in vertical electrophoresis system (Shelton scientific inc., USA) using 8 per cent polyacrylamide gel electrophoresis (PAGE) which resulted in 203, 138, 126, 71 bp for wild type, 274, 203, 138, 126 and 71 bp for heterozygous variant and 274, 138 and 126 bp for homozygous variant (23).
Statistical analysis: Statistical analysis was done using the SPSS, version 13 (SPSS Inc., Chicago, Illinois, USA). The demographic details of cases and controls with continuous variables were compared using Student unpaired t test while categorical variables, allele and genotype frequencies between hypertensives and normotensives, and Hardy-Weinberg equilibrium was calculated using chi-square analysis. The association between genotypes and hypertension risk was analyzed by calculating the odds ratio (OR) and 95 per cent confidence interval (95% CI). Logistic regression analysis was used to adjust the potential confounders for hypertension such as age, smoking and alcohol consumption with the low risk genotype designated as reference category. P<0.05 was considered as statistically significance.
The mean age was significantly higher in controls when compared to cases (P<0.001). There was a significant difference in SBP, DBP, smoking, alcohol intake, total cholesterol, LDL, and VLDL cholesterol level among the cases and controls (Table I). Confounding factors that revealed significant difference, except BP, were taken for multiple logistic regression analysis.
The different restriction fragments of CYP11B2 C-344T gene variant are shown in the Fig. The homozygous variant genotype T/T was significantly higher in hypertensive cases when compared to the controls (OR-1.8; 95% CI: 1.1-2.8, P=0.02) after adjusting the confounding factors. The variant allele T was also higher in the cases when compared to the controls (66.6 vs. 60.1%, P=0.007) (Table II). The observed and expected genotype frequencies were in concordance with the Hardy-Weinberg equilibrium.
Gender-wise analysis showed, the frequency of homozygous variant genotype T/T (OR-1.8; 95% CI: 1.0-3.6, P=0.05) and variant allele T (66.1 vs 58.2%) was significantly higher in male cases when compared to male controls, but there was no difference among the female cases and controls (Table III).
Meta analysis on C-344T polymorphism among major ethnics: A meta analysis comprising 24 studies including the present study showed that the overall prevalence of C and T allele amounted to 39 and 61 per cent respectively in 15,059 subjects (Table IV). Further, the risk of hypertension was estimated by combining 10 case-control studies, including the present study. The odds ratio for hypertension was 1.4 (95% CI: 1.2-1.7, P<0.0001) and 1.2 (95% CI: 1.0-1.4, P<0.05) for C/T heterozygous and TT homozygous genotype respectively as compared to CC homozygous genotype (6,12-14,21,23-26).
Hypertension, a major risk factor for cardiovascular and renal disease, is predicted to increase cardiovascular deaths by 111 per cent in India by 2020, much more than in any other Asian country (1). Hypersecretion of aldosterone was authenticated to cause hypertension. The variations in CYP11B2 gene, influences the aldosterone synthesis (27).
In our study, the homozygous variant TT genotype and variant allele
T was significantly higher in hypertensive cases than the controls. Several studies have investigated the association between CYP11B2 polymorphism and essential hypertension among different ethnic groups, with conflicting results (6,11,14).
A case-control study conducted among Indians living in highland, with smaller sample size, did not find significant association between C-344T polymorphism and hypertension. The study showed a significant association with BMI but the subjects had mean BMI below 25 kg/[m.sup.2] which is not considered as a risk factor for hypertension (21). Another Indian study reported that T allele was highly prevalent in highlanders as compared to lowlanders of north India (28). In accordance with this study, ours showed a higher prevalence of T allele in both hypertensives and normotensives. A case-control study conducted in French and Scottish Caucasian population showed that the variant allele T was highly prevalent in hypertensive cases and significantly associated with hypertension (6,12).
When the influence of C-344T polymorphism was analyzed separately for male and female participants, variant allele T was found to be significantly higher and the homozygous genotype T/T had a marginal significant association in male hypertensive cases, but not in the female subjects. Further, the present study did not show any gene-sex interaction. A study conducted in Chinese population did not find any gender-specific association with hypertension, whereas a study done in Australian population showed that female hypertensive cases with C allele were at increased risk of hypertension (24,25). The underlying cause to develop hypertension was limited to female cases, suggesting that this polymorphism could interact with the Y chromosome (24). Our study suggests that the risk was confined to male hypertensives and the reason for this has to be further evaluated.
A larger community-based study in Japanese population revealed that C-344T polymorphism was not associated with blood pressure levels in either sex (17). Variations in CYP11B2 C-344T have been shown to be associated with increased blood pressure levels, plasma and urinary levels of aldosterone, and plasma renin levels (6,21,29). We could not analyze the mean blood pressure and plasma aldosterone levels in cases since many of our subjects were on antihypertensive medication which might influence the study. When the blood pressure level was analyzed in healthy volunteers, significant difference was not observed among the genotypes (data not shown). However, the results of our study are in agreement with the Caucasian study that did not show significant association between blood pressure and C-344T genotypes (29). There was a linear increase in diastolic blood pressure in 344T allele carriers with increase in age in the Italian population (30). Another study conducted in elderly Caucasian population reported that systolic blood pressure was higher in TT genotypes, compared to CC genotypes (31).
Association of genetic polymorphisms with complex polygenic disorders such as hypertension is further strengthened by haplotype and linkage disequilibrium analysis. CYP11B2 C-344T polymorphism was found to be in linkage disequilibrium with other CYP11B2 Int2W/C and K173R polymorphisms (21). Aldosterone-renin ratio was found to be significantly higher in hypertensive cases with haplotype combination of variant alleles 344T and Int2C when compared to other haplotype combinations (9).
Inter-ethnic variation exists in the polymorphism of C-344T polymorphism. A meta-analysis was carried out to examine the prevalence of C-344T polymorphism among different ethnics (Table IV). There is significant heterogeneity among the reports, with some studies showing association with T allele and others with C allele. The difference could be attributed to variations in environmental factors, apart from the differences in the selection of cases and controls, sample size, age, BMI, and other ecological factors.
In conclusion, the present study shows an association between C-344T polymorphism and essential hypertension in a south Indian Tamil population, and the risk has been found to be a predisposing factor in males. Since hypertension is a polygenic disorder influenced by multiple genes, further association studies and screening of other candidate gene polymorphisms is required to elucidate the precise genetic susceptibility of essential hypertension.
This study was funded by the Department of Biotechnology, New Delhi (Ref No: D.O. No.BT/PR4076/Med/12/163/2003 dated 1/12/2004). The authors wish to thank Shri Balamurali for technical assistance.
(1.) Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004; 18 : 73-8.
(2.) Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de La Sierra A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 2001; 38 : 1204-9.
(3.) Freel EM, Connell JM. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol 2004; 15 : 1993-2001.
(4.) Hilgers KF, Schmidt BM. Gene variants of aldosterone synthase and hypertension. J Hypertens 2005; 23 : 1957-9.
(5.) Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass and function. Circulation 1998; 97 : 569-75.
(6.) Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32 : 198-204.
(7.) White PC, Rainey WE. Polymorphisms in CYP11B genes and 11-hydroxylase activity. J Clin Endocrinol Metab 2005; 90 : 1252-5.
(8.) Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE. Differential regulation of aldosterone synthase and 11 betahydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol 2002; 28 : 125-35.
(9.) Nicod J, Bruhin D, Auer L, Vogt B, Frey FJ, Ferrari P. A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J Clin Endocrinol Metab 2003; 88 : 2495-500.
(10.) Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl AcadSci USA 1992; 89 : 4996-5000.
(11.) Matsubara M, Sato T, Nishimura T, Suzuki M, Kikuya M, Metoki H, et al. CYP11B2 polymorphisms and home blood pressure in a population-based cohort in Japanese: the Ohasama study. Hypertens Res 2004; 27 : 1-6.
(12.) Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999; 33 : 703-7.
(13.) Tsukada K, Ishimitsu T, Teranishi M, Saitoh M, Yoshii M, Inada H, et al. Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. J Hum Hypertens 2002; 16 : 789-93.
(14.) Tang W, Wu H, Zhou X, Cheng B, Dong Y, He L, et al. Association of the C-344T polymorphism of CYP11B2 gene with essential hypertension in Hani and Yi minorities of China. Clin Chim Acta 2006; 364 : 222-5.
(15.) Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A, Muscholl MW, et al. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation 1999; 99 : 2255-60.
(16.) Tiret L, Mallet C, Poirier O, Nicaud V, Millaire A, Bouhour JB, et al. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol 2000; 35 : 29-35.
(17.) Yamagishi K, Tanigawa T, Cui R, Tabata M, Ikeda A, Yao M, et al. Aldosterone synthase gene T-344C polymorphism, sodium and blood pressure in a free-living population: A community based study. Hypertens Res 2007; 30 : 497-502.
(18.) Hengstenberg C, Holmer SR, Mayer B, Lowel H, Engel S, Hense HW, et al. Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension 2000; 35 : 704-9.
(19.) Stella P, Bigatti G, Tizzoni L, Barlassina C, Lanzani C, Bianchi G, et al. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 2004; 43 : 265-70.
(20.) Barbatoa A, Russo P, Siani A, Folkerd EJ, Miller MA, Venezia A, et al. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens 2004; 22 : 1895-901.
(21.) Rajput C, Makhijani K, Norboo T, Afrin F, Sharma M, Pasha ST, et al. CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake. J Hypertens 2005; 23 : 79-86.
(22.) Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328 : 634-40.
(23.) Komiya I, Yamada T, Takara M, Asawa T, Shimabukuro M, Nishimori T, et al. Lys(173)Arg and -344T/C variants of CYP11B2 in Japanese patients with low-renin hypertension. Hypertension 2000; 35 : 699-703.
(24.) Kumar NN, Benjafield AV, Lin RC, Wang WY, Stowasser M, Morris BJ. Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. J Hypertens 2003; 21 : 1331-7.
(25.) Gu D, Ge D, He J, Li B, Chen J, Liu D, et al. Haplotypic analyses of the aldosterone synthase gene CYP11B2 associated stage-2 hypertension in northern Han Chinese. Clin Genet 2004; 66 : 409-16.
(26.) Tamaki S, Iwai N, Tsujita Y, Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 1999; 33 : 266-70.
(27.) Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekalski S, et al. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 1999; 34 : 423-9.
(28.) Rajput C, Arif E, Vibhuti A, Stobdan T, Khan AP, Norboo T, et al. Predominance of interaction among wild-type alleles of CYP11B2 in Himalayan natives associates with high-altitude adaptation. Biochem Biophys Res Commun 2006; 348 : 73540.
(29.) Pojoga L, Gaultier S, Blanc H, Guyene TT, Poirier O, Cambien F, et al. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998; 11 : 856-60.
(30.) Russoa P, Siania A, Venezia A, Iacone R, Russo O, Barba G, et al. Interaction between the C(-344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 2002; 20 : 1785-92.
(31.) Casiglia E, Tikhonoff V, Mazza A, Rynkiewicz A, Limon J, Caffi S, et al. C-344T polymorphism of the aldosterone synthase gene and blood pressure in the elderly: a population-based study. J Hypertens 2005; 23 : 1991-6.
(32.) Lim PO, MacDonald TM, Holloway C, Friel E, Anderson NH, Dow E, et al. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J Clin Endocrinol Metab 2002; 87 : 4398-402.
(33.) Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R, et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet 2006; 7 : 42.
(34.) Hautanen A, Toivanen P, Manttari M, Tenkanen L, Kupari M, Manninen V, et al. Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation 1999; 100 : 2213-8.
S. Rajan, P. Ramu, G. Umamaheswaran & C. Adithan
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, India
Received March 30, 2009
Reprint requests: Dr Adithan Chandrasekaran, Pharmacogenomics Laboratory, Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry 605 006, India e-mail: firstname.lastname@example.org
Table I. Demographic details and biochemical parameters of the study subjects Parameters Cases Controls (n=406) (n=424) Sex (Male : Female) 200 : 206 183 : 241 Age (yr) 44.1 [+ or -] 0.4 ** 47.3 [+ or -] 0.4 BMI (kg/[m.sup.2]) 23.0 [+ or -] 0.3 23.1 [+ or -] 0.2 SBP (mm Hg) 152.6 [+ or -] 0.8 ** 118.0 [+ or -] 0.5 DBP (mm Hg) 97.2 [+ or -] 0.5 ** 78.1 [+ or -] 0.3 Smoking Yes 71 (17.5%) ** 34 (8.0%) No 335 (82.5%) 390 (92%) Alcohol Yes 109 (26.8%) * 84 (19.8%) No 297 (73.2%) 340 (80.2%) Serum total cholesterol 175.6 [+ or -] 1.4 * 170.2 [+ or -] 1.6 (mg/dl) Serum triglycerides 118.0 [+ or -] 2.3 115.6 [+ or -] 2.5 (mg/dl) Serum HDL (mg/dl) 40.6 [+ or -] 0.4 41.1 [+ or -] 0.5 Serum LDL (mg/dl) 110.6 [+ or -] 1.3 * 106.6 [+ or -] 1.4 Serum VLDL (mg/dl) 24.3 [+ or -] 0.5 * 22.5 [+ or -] 0.4 Values are expressed as mean [+ or -] SEM or numbers and percentages * P<0.05, ** <0.001 compared to controls Table II. Genotype and allele frequencies of CYP11B2 C-344T polymorphism among the cases and controls CYP11B2 Cases Controls Unadjusted OR P (n=406) (n=424) (95% CI) value Genotype: C/C 43 (10.6) 56 (13.2) 1.0 C/T 185 (45.6) 226 (53.3) 1.1 (0.7-1.7) 0.8 T/T 178 (43.8) 142 (33.5) 1.6 (1.0-2.6) 0.04 Allele: C 271 (33.4) 338 (39.9) T 541 (66.6) 510 (60.1) 1.3 (1.1-1.6) 0.007 CYP11B2 Adjusted OR P ( 95% CI ) value Genotype: C/C 1.0 C/T 1.2 (0.9-2.0) 0.4 T/T 1.8 (1.1-2.8) 0.02 Allele: C T -- -- Values in parenthesis indicate percentages Odds ratio adjusted for confounding factors (age, sex, smoking and alcohol consumption) Table III. Gender specific distribution of aldosterone synthase CYP11B2 C-344T gene polymorphism among the study subjects CYP11B2 Male subjects C-344T Cases Controls OR P (n = 200) (n = 183) (95% CI) Genotypes: CC 22 (11) 31 (17.0) 1.0 CT 91 (45.5) 91 (49.7) 1.4 (0.8-2.6) 0.3 TT 87 (43.5) 61 (33.3) 2.0 (1.1-3.8) 0.04 Alleles: C 33.9 41.8 T 66.1 58.2 1.4 (1.04-1.9) 0.02 CYP11B2 Female subjects C-344T OR * P Cases Controls (95% CI) (n = 206) (n=241) Genotypes: CC 1.0 21 (10.2) 25 (10.4) CT 1.3 (0.7-2.5) 0.5 94 (45.6) 135 (56.0) TT 1.8 (1.0-3.6) 0.05 91 (44.2) 81 (33.6) Alleles: C 33.0 38.4 T -- -- 67.0 61.6 CYP11B2 C-344T OR P OR * P (95% CI) (95% CI) Genotypes: CC 1.0 1.0 CT 0.8 (0.4-1.5) 0.6 0.8 (0.4-1.7) 0.6 TT 1.3 (0.7-2.6) 0.4 1.4 (0.7-2.8) 0.4 Alleles: C T 1.3 (0.95-1.7) 0.1 -- -- Values in parenthesis indicate percentage * Odds ratio according to genotypes were estimated after adjusting the confounding variables for smoking and alcohol consumption in male subjects and for age in female subjects Table IV. Summary of the influence of CYP11B2 C-344T polymorphism on various ethnic populations Author Population Cardiovascular disorder Poch et al (2) Spanish EH Kupari et al (5) Finnish Healthy volunteers Brand et al (6) French EH Nicod et al (9) Swiss EH Matsubara et al (11) Japanese EH Davies et al (12) Scottish EH Tsukada et al (13) Japanese EH Tang et al (14) Chinese EH Schunkert et al (15) Germans LVH Tiret et al (16) French IDC Yamagishi et al (17) Japanese BP Hengstenberg Germans MI et al (18) Stella et al (19) Italians EH Barbato et al (20) Whites Africans PA, ARR,BP Asians Rajput et al (21) Indians EH (Highlanders) Komiya et al (23) Japanese EH Kumar et al (24) Australian EH Gu et al (25) Chinese EH Tamaki et al (26) Japanese Hypertension Russoa et al (30) Italian Healthy volunteers Lim et al32 Whites (English) Hypertension Prasad et al (33) Indians DM CRI (DM) Hautanen et al (34) Finnish MI Present study South Indians EH (Tamil population) Author Sample size % T allele Associated (case/control) frequency allele Poch et al (2) 66 64 NS Kupari et al (5) 84 51 C Brand et al (6) 380/293 56/49 * T Nicod et al (9) 141 53 T Matsubara et al (11) 1242 65 T Davies et al (12) 138/138 60/53 * T Tsukada et al (13) 250/221 66/73 * C Tang et al (14) 271/267 78/86 * C Schunkert et al (15) 562 58 NS Tiret et al (16) 433/401 57/54 * NS Yamagishi et al (17) 2823 67 NS Hengstenberg 606 56 NS et al (18) Stella et al (19) 210 54 T Barbato et al (20) 456 55 T 441 79 416 56 Rajput et al (21) 100/190 64/70 * C Komiya et al (23) 73/134 66/63 * C Kumar et al (24) 146/291 48/58 * C Gu et al (25) 503/503 70/68 * NS Tamaki et al (26) 255/227 74/68 * C Russoa et al (30) 811 52 T Lim et al32 325 53 T Prasad et al (33) 196 64 T 225 73 Hautanen et al (34) 141/270 48/53 * C Present study 406/424 67/60 * T Author Study type Poch et al (2) Cross-sectional Kupari et al (5) Healthy controls Brand et al (6) Case control Nicod et al (9) Cross-sectional Matsubara et al (11) Cross-sectional Davies et al (12) Case control Tsukada et al (13) Case control Tang et al (14) Case control Schunkert et al (15) Cross-sectional Tiret et al (16) Case control Yamagishi et al (17) Cross-sectional Hengstenberg Cross-sectional et al (18) Stella et al (19) Cross-sectional Barbato et al (20) Cross-sectional Rajput et al (21) Case control Komiya et al (23) Case control Kumar et al (24) Case control Gu et al (25) Case control Tamaki et al (26) Case control Russoa et al (30) Cross sectional Lim et al32 Cross sectional Prasad et al (33) Cross sectional Hautanen et al (34) Case control Present study Case control EH, essential hypertension; ARR, aldosterone renin ratio; BP, blood pressure; LVH, left ventricular hypertrophy; PA, plasma aldosterone; CRI, chronic renal insuffiency; DM, diabetes mellitus; IDC, idiopathic dilated cardiomyopathy; MI, myocardial infarction. NS indicates that the study was not significant for either T or C allele; * indicates the percentage of T allele frequency for case group/control group of case--control study
|Printer friendly Cite/link Email Feedback|
|Author:||Rajan, S.; Ramu, P.; Umamaheswaran, G.; Adithan, C.|
|Publication:||Indian Journal of Medical Research|
|Date:||Oct 1, 2010|
|Previous Article:||Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases.|
|Next Article:||High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.|